Accessibility Menu
GeneDx logo

GeneDx(NASDAQ) WGS

Market Cap$2.57BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-73%
5 Year-71%
1 Year-33%
1 Month+36%
Premium Feature
Moneyball Superscore
65/100
$86.34
-3.25%
-2.90Today
GeneDx last closing stock price
MetricPriceDate
Last closeUSD 86.342026-08-28
GeneDx stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.84%USD 87.072026-08-21
1 month+35.57%USD 63.692026-07-29
3 month+66.06%USD 51.992026-05-29
Year to date-33.62%USD 130.062025-12-31
1 year-33.07%USD 129.002025-08-28
3 year+1,797.47%USD 4.552023-08-29
5 year-71.34%USD 301.292021-08-27
Since inception-73.3%USD 323.402020-11-04

GeneDx Financials at a Glance

Market Cap

$2.57BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$454.43M

Net Income (TTM)

-$106.36M

EPS (TTM)

-$3.63

P/E Ratio

-23.79

Dividend

$0.00

Beta (Volatility)

1.85 (High)

Price

$86.34

Volume

435,340.975

Open

$88.79

Previous Close

$86.34

Daily Range

$85.93 - $89.74

52-Week Range

$32.21 - $170.87

Estimated Earnings Date

Oct 27, 2026

WGS News

SellAlert-Green.png

What a $227,000 GeneDx Insider Sale Means as Revenue Climbs 17%

Jonathan PoncianoJun 23, 2026
Insider.png

Hedge Funder Eli Casdin Is Loading up on GeneDx Shares

Brendan CoffeyJun 11, 2026
BuyAlert-Green.png

This Healthcare Investor Added $43 Million to a Genomics Leader Growing Volume 34%

Jonathan PoncianoMay 23, 2026
BuyAlert-Purple.png

Is GeneDx Stock a Buys After a Company Director Purchased Over 350,000 Shares?

Robert IzquierdoMay 21, 2026
GettyImages-1409383663 (1)

Why GeneDX Stock Is Plummeting Today

Keith NoonanMay 5, 2026
SellAlert-Red.png

GeneDx's Chief Operating Officer Sold Nearly 6,000 Shares. Is the Stock a Buy or Sell?

Robert IzquierdoFeb 26, 2026
SellAlert-Green.png

GeneDX CEO Sells 2,158 Shares After 84% One-Year Bump

Sarah SidlowDec 9, 2025
institutional.png

BOSUN Sells All 70K GeneDx Holdings Corp. Shares—Should Investors Follow Suit?

Adam PalascianoNov 14, 2025
Page 1

WGS: Motley Fool Moneyball Superscore

65

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About GeneDx

GeneDx Holdings Corp. helps doctors and patients understand genetic information. It uses artificial intelligence to look at DNA to find treatments for rare diseases. These services help people get the right medical care faster.

Mapping the Human Code

  • Exome and Genome Sequencing: Diagnostic tests that scan the entire protein-coding region or whole genome; represented 49% of all test results in the three months ended June 30, 2026.
  • Diagnostic Testing Services: Genetic tests provided to healthcare professionals and hospitals; generated $111.9 million in revenue for the three months ended June 30, 2026.
  • Collaboration Services: Support for biopharmaceutical companies including health information and patient identification; recorded as other revenue in financial reports.
  • Software and Interpretation: Artificial intelligence tools used by clinical laboratories and hospitals for analyzing hereditary risks and cancer.

Growing the Business

  • Acquired Fabric Genomics in 2025 to enhance software and AI-enabled interpretation services.
  • Entered into a $100 million loan agreement with Blackstone in Feb. 2026 to support operations.
  • Expanded the commercial organization through a significant increase in sales representative headcount in 2026.
  • Amended the Blackstone loan agreement in Aug. 2026 to add a $50 million term loan facility.

The Centrellis Platform

GeneDx uses its Centrellis platform to apply machine learning to large clinical and genomic data sets. This technology creates dynamic models of human health to find personalized pathways for patient well-being.

A Look at the Finances

  • Total revenue rose 11% to $114.4 million for the three months ended June 30, 2026.
  • Net loss was $17.7 million for the three months ended June 30, 2026.
  • Non-cash impairment charges totaled $31.3 million during the first quarter of 2026.
  • Cash and marketable securities totaled $132.5 million as of June 30, 2026.

Bottom Line

GeneDx has evolved from a private firm established in 2015 into a public health intelligence company. Its strategy relies on scaling its genomic database and using automated interpretation to support clinical decisions.

AI Generated • Aug 4, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

Employees

1,300

CEO

Katherine A. Stueland

Website

www.genedx.com

Headquarters

Stamford, CT 06902, US

WGS Financials

Key Financial Metrics (TTM)

Gross Margin

68.20%

Operating Margin

-13.34%

Net Income Margin

-23.40%

Return on Equity

-38.72%

Return on Capital

-2.56%

Return on Assets

-22.09%

Earnings Yield

-4.20%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.57BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

29.82M

Volume

435.34K

Avg. Volume

865.28K

Financials (TTM)

Gross Profit

$309.90M

Operating Income

-$60.61M

EBITDA

-$76.43M

Operating Cash Flow

-$48.71M

Capital Expenditure

-$27.09M

Free Cash Flow

-$75.80M

Cash & ST Invst.

$132.55M

Total Debt

$167.40M

GeneDx Performance Analysis

GeneDx annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 234,694,00010.6%
20232023-12-31USD 202,566,000-13.7%
20242024-12-31USD 305,450,00050.8%
20252025-12-31USD 427,539,00040.0%
GeneDx sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3013.7%
Q42025-12-313.6%
Q12026-03-31-15.5%
Q22026-06-3011.9%
GeneDx annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -53.63-28.4%
20232023-12-31USD -7.23-86.5%
20242024-12-31USD -1.94-73.1%
20252025-12-31USD -0.73-62.3%
GeneDx sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-175.0%
Q42025-12-31-118.5%
Q12026-03-31-266.1%
Q22026-06-3072.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$114.44M

+11.4%

Gross Profit

$78.24M

+10.3%

Gross Margin

68.37%

N/A

Market Cap

$2.57BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.98M

N/A

Employees

1,300

N/A

Net Income

-$17.74M

-264.1%

EBITDA

-$10.36M

-159.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$132.55M

-1.5%

Total Debt

$167.40M

+46.3%

Accounts Receivable

$83.61M

+74.1%

Inventory

$17.82M

+49.3%

Long Term Debt

$161.69M

+45.3%

Short Term Debt

$5.71M

+85.2%

Return on Assets

-22.09%

N/A

Return on Invested Capital

-14.90%

N/A

Free Cash Flow

-$39.10M

-585.6%

Operating Cash Flow

-$28.98M

-378.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PRVAPrivia Health Group, Inc.
$20.79-0.34%
NAMSNewAmsterdam Pharma Company N.V.
$25.90-3.32%
TMDXTransMedics Group, Inc.
$88.43-3.62%
OPCHOption Care Health, Inc.
$23.90-0.33%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$49.82+0.10%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$111.34-0.10%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$38.54+0.02%
INTCIntel
$89.47-0.03%

Questions About WGS

What is the current price of GeneDx?

GeneDx is trading at $86.34 per share.

What is the 52-week range for GeneDx?

Over the past 52 weeks, GeneDx has traded between $32.21 and $170.87.

How much debt does GeneDx have?

As of the most recent reporting period, GeneDx reported total debt of $167.40M.

How much cash does GeneDx have on hand?

GeneDx reported $60.32M in cash and cash equivalents in its most recent financial results.

What is GeneDx’s dividend yield?

GeneDx does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services